Efficacy and safety of medical cannabinoids in older subjects: A systematic review

@article{Elsen2014EfficacyAS,
  title={Efficacy and safety of medical cannabinoids in older subjects: A systematic review},
  author={G. V. D. Elsen and A.I.A. Ahmed and M. Lammers and C. Kramers and R. Verkes and M. Marck and M. Rikkert},
  journal={Ageing Research Reviews},
  year={2014},
  volume={14},
  pages={56-64}
}
This systematic review aims to integrate the evidence on indications, efficacy, safety and pharmacokinetics of medical cannabinoids in older subjects. The literature search was conducted using PubMed, EMBASE, CINAHL and Cochrane Library. We selected controlled trials including solely older subjects (≥65 years) or reporting data on older subgroups. 105 (74%) papers, on controlled intervention trials, reported the inclusion of older subjects. Five studies reported data on older persons separately… Expand
Clinical pharmacology of oral tetrahydrocannabinol in older people with dementia
TLDR
Two studies showed that THC might be useful in treatment of anorexia and behavioral symptoms in dementia, and adverse events were more common during cannabinoid treatment compared to the control treatment, and were most frequently sedation like symptoms. Expand
Tetrahydrocannabinol in the treatment of neuropsychiatric symptoms in dementia
TLDR
Two studies showed that THC might be useful in treatment of anorexia and behavioral symptoms in dementia, and adverse events were more common during cannabinoid treatment compared to the control treatment, and were most frequently sedation like symptoms. Expand
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
TLDR
There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Expand
Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis
TLDR
This pooled analysis, using data from RCTs with mean participant age ≥50 years, suggests that although THC-containing CBMs are associated with side effects, CBMs in general are safe and acceptable in older adults. Expand
Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies
TLDR
A meta-analysis of open-label observational studies of cannabinoid-based medications for all indications in individuals with a mean age of ≥50 years found cannabinoids were generally safe and acceptable to adults aged over 50 years. Expand
Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews
TLDR
Herbal cannabis cannot be recommended as first- or second-line therapy for CINV with safe and effective antiemetics available, due to the lack of RCT data and safety concerns. Expand
Medical Cannabis for Older Patients
TLDR
A pragmatic clinical approach to a rational dialogue with older patients is proposed, highlighting the importance of individual benefit–risk assessment and shared patient–clinician decision making. Expand
Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis
TLDR
Treatment efficacy was associated with baseline dementia severity and dose, but not dementia subtype, age, or sex, and preliminary evidence for the efficacy and tolerability of cannabinoids as treatments for NPS is found. Expand
Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
TLDR
Evidence on medical uses of cannabis is broad, however, due to methodological limitations, conclusions were weak in most of the assessed comparisons, and evidence mapping methodology is useful to perform an overview of available research. Expand
Cannabinoids in the Older Person: A Literature Review
TLDR
Risks of cannabinoids in older patients appear to be moderate, and their frequency comparable to other analgesic drug classes, however, the quality of research is weak, and few older patients have been enrolled in cannabinoid studies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Adverse effects of medical cannabinoids: a systematic review
TLDR
Short-term use of existing medical cannabinoids appeared to increase the risk of nonserious adverse events, and high-quality trials of long-term exposure are required to further characterize safety issues related to the use of medical cannabinoids. Expand
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
TLDR
Cannabinoids including the cannabidiol/THC buccal spray are effective in treating neuropathic pain in MS, and cannabinoids were superior to placebo at endpoint. Expand
Cannabinoids for epilepsy.
TLDR
No reliable conclusions can be drawn at present regarding the efficacy of cannabinoids as a treatment for epilepsy because the dose of 200 to 300 mg daily of cannabidiol was safely administered to small numbers of patients generally for short periods of time, and so the safety of long term cannabids treatment cannot be reliably assessed. Expand
Cannabinoids for the treatment of dementia.
TLDR
This review finds no evidence that cannabinoids are effective in the improvement of disturbed behaviour in dementia or in the treatment of other symptoms of dementia. Expand
The Medicinal Use of Cannabis and Cannabinoids—An International Cross-Sectional Survey on Administration Forms
TLDR
The survey was completed by 953 participants from 31 countries, making this the largest international survey on a wide variety of users of cannabinoid-based medicine performed so far, and in general, herbal non-pharmaceutical CBMs received higher appreciation scores by participants than pharmaceutical products containing cannabinoids. Expand
Cannabis for dyskinesia in Parkinson disease
TLDR
Orally administered cannabis extract resulted in no objective or subjective improvement in dyskinesias or parkinsonism in Parkinson disease patients. Expand
Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
TLDR
Omnisol gives a quick onset of pharmacodynamic effects in healthy volunteers, which implies a rapid initiation of therapeutic effects in patients and showed promising PK and PD characteristics. Expand
Cannabidiol for the treatment of psychosis in Parkinson’s disease
TLDR
Preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD. Expand
Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration
TLDR
Sativex has a pharmacodynamic safety profile comparable to that of oral THC at low, therapeutic doses, and produces similar, clinically insignificant increases in heart rate, anxiety, and “good drug effects” with no serious adverse events. Expand
Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease
TLDR
It is indicated that dronabinol is a promising novel therapeutic agent which may be useful not only for treatment of anorexia but also to improve disturbed behavior in patients with Alzheimer's disease. Expand
...
1
2
3
4
5
...